Search results for " pharmacy."

showing 10 items of 356 documents

Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.

2020

In this paper the innovative approach of Nano into micro (NiM9 was developed to produce Nanoparticles loaded Ivacaftor to incorporate into mannitol or mannitol/cysteamine micromatrices for drug pulmonary administration in CF. Nanoparticles composed by a mixture of two polyhydrohydroxyethtylaspartamide copolymers containing a loading of Ivacaftor of 15.5 % w/w were produced. These Nanoparticles were incorporated into microparticles to obtain NiM that were characterized in terms of size and size distribution, interaction with CF-AM by rheological and turbidimetric studies as well as by aerodynamic diameter measurements. Finally the activity of Ivacaftor into these NiM was evaluated by in vitr…

Cystic Fibrosisαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) copolymer PHEA ivacaftor mucus-penetrating nanoparticle cell penetrating peptide nano into micro strategy. CysteamineDrug CompoundingPharmaceutical ScienceNanoparticleCystic Fibrosis Transmembrane Conductance Regulator02 engineering and technologyQuinolonesAminophenols030226 pharmacology & pharmacyIvacaftor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNano-Administration InhalationMucus-penetrating nanoparticlemedicineCopolymerAnimalsMannitolChloride Channel AgonistsCells CulturedExpectorantsCell penetrating peptideNano into micro strategyChemistry021001 nanoscience & nanotechnologyMucusRats Inbred F344IvacaftorCopolymer PHEADrug LiberationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMutationNanoparticlesCysteamineMannitolPowders0210 nano-technologyPeptidesαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA)medicine.drugNuclear chemistryInternational journal of pharmaceutics
researchProduct

A Xenogeneic-Free Protocol for Isolation and Expansion of Human Adipose Stem Cells for Clinical Uses

2013

Human adipose stem cells (hASCs) play a crucial role in the fields of regenerative medicine and tissue engineering for different reasons: the abundance of adipose tissue, their easy harvesting, the ability to multipotent differentiation and the fact that they do not trigger allogeneic blood response or secrete cytokines that act as immunosuppressants. The vast majority of protocols use animal origin reagents, with the underlying risk of transmitting infections by non-human pathogens. We have designed a protocol to isolate and maintain the properties of hASCs avoiding xenogeneic reagents. These changes not only preserve hASCs morphology, but also increase cell proliferation and maintain thei…

Cèl·lules mare neuralsCellular differentiationCell- and Tissue-Based TherapyAdipose tissueCell SeparationStem cell markerRegenerative MedicineRegenerative medicine0302 clinical medicineTissue engineeringMolecular Cell BiologyAdipocytesNeurociènciesGene Regulatory Networks0303 health sciencesMultidisciplinaryStem CellsQRGene Expression Regulation DevelopmentalCell Differentiation3. Good healthCell biologyAdult Stem Cells317 Pharmacy030220 oncology & carcinogenesisMedicineStem cellCellular TypesMetabolic Networks and PathwaysResearch ArticleBiotechnologyAdultAdolescentClinical Research DesignScienceCell PotencyPrimary Cell CultureBiologyCell Growth03 medical and health sciencesYoung AdultAnimalsHumansBiology030304 developmental biologyCell ProliferationTissue EngineeringGene Expression ProfilingMesenchymal stem cellCell cultureImmunologyBiomarkersDevelopmental BiologyPLoS ONE
researchProduct

Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.

2005

Abstract Background: Tacrolimus is metabolized predominantly to 13-O-demethyltacrolimus in the liver and intestine by cytochrome P450 3A (CYP3A). Patients with high concentrations of CYP3A5, a CYP3A isoenzyme polymorphically produced in these organs, require higher doses of tacrolimus, but the exact mechanism of this association is unknown. Methods: cDNA-expressed CYP3A enzymes and a bank of human liver microsomes with known CYP3A4 and CYP3A5 content were used to investigate the contribution of CYP3A5 to the metabolism of tacrolimus to 13-O-demethyltacrolimus as quantified by liquid chromatography–tandem mass spectrometry. Results: Demethylation of tacrolimus to 13-O-demethyltacrolimus was …

DNA ComplementaryCYP3AClinical BiochemistryPharmacologyBiologyIn Vitro Techniques030226 pharmacology & pharmacyTacrolimus03 medical and health sciences0302 clinical medicinePharmacokineticsCytochrome P-450 Enzyme SystemCytochrome P-450 CYP3AHumansCYP3A7030304 developmental biologyDemethylation0303 health sciencesCYP3A4Biochemistry (medical)MetabolismTacrolimusMicrosomeMicrosomes LiverBaculoviridaeImmunosuppressive AgentsClinical chemistry
researchProduct

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with…

2020

Oral drug absorption is a complex process depending on many factors, including the physicochemical properties of the drug, formulation characteristics and their interplay with gastrointestinal physiology and biology. Physiological-based pharmacokinetic (PBPK) models integrate all available information on gastro-intestinal system with drug and formulation data to predict oral drug absorption. The latter together with in vitro-in vivo extrapolation and other preclinical data on drug disposition can be used to predict plasma concentration-time profiles in silico. Despite recent successes of PBPK in many areas of drug development, an improvement in their utility for evaluating oral absorption i…

Data AnalysisPhysiologically based pharmacokinetic modellingDatabases FactualAdministration OralPharmaceutical Science02 engineering and technologyMachine learningcomputer.software_genreModels Biological030226 pharmacology & pharmacyBiopharmaceuticsPharmaceutical Sciences03 medical and health sciences0302 clinical medicineSoftwarePharmacokineticsHumansClinical Trials as Topicbusiness.industryCompound specificBiopharmaceuticsGeneral MedicineFarmaceutiska vetenskaper021001 nanoscience & nanotechnologyBioavailabilityIntestinal AbsorptionPharmaceutical PreparationsDrug developmentPerformance indicatorArtificial intelligence0210 nano-technologybusinesscomputerSoftwareForecastingBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

New Author Guidelines for Displaying Data and Reporting Data Analysis and Statistical Methods in Experimental Biology

2019

The American Society for Pharmacology and Experimental Therapeutics has revised the Instructions to Authors for Drug Metabolism and Disposition, Journal of Pharmacology and Experimental Therapeutics, and Molecular Pharmacology These revisions relate to data analysis (including statistical analysis) and reporting but do not tell investigators how to design and perform their experiments. Their overall focus is on greater granularity in the description of what has been done and found. Key recommendations include the need to differentiate between preplanned, hypothesis-testing, and exploratory experiments or studies; explanations of whether key elements of study design, such as sample size and …

Data AnalysisSocieties Scientific0301 basic medicineResearch designBiomedical ResearchComputer scienceBar chartDrug Evaluation PreclinicalMEDLINEPharmaceutical ScienceGuidelines as TopicBiostatistics030226 pharmacology & pharmacylaw.invention03 medical and health sciences0302 clinical medicinelawHumansStatistical hypothesis testingPeer Review ResearchPublishingPharmacologyInformation retrievalUnited StatesConfidence interval3. Good health030104 developmental biologyData pointResearch DesignSample size determinationData Interpretation Statistical030220 oncology & carcinogenesisScatter plotPractice Guidelines as TopicOutlierMolecular MedicinePeriodicals as TopicEditorial Policies030217 neurology & neurosurgeryDrug Metabolism and Disposition
researchProduct

Nationwide evaluation of day-to-day clinical pharmacists' interventions in German hospitals.

2015

tudy Objective To describe and evaluate the extent and diversity of nationwide data from clinical pharmacists’ interventions (PIs) in German hospitals. Design Retrospective analysis. Data Source The ADKA-DokuPIK German database, a national anonymous self-reported Internet-based documentation system for routine PIs as well as for medication errors reported by German hospital pharmacists. Measurements and Main Results Data sets from ADKA-DokuPIK entered between January 2009 and December 2012 were analyzed descriptively. A total of 27,610 PIs were entered, mainly by ward-based clinical pharmacists (82.5%). Most of the PIs were performed on surgical wards (37.8%), followed by anesthesiology/int…

Data sourcemedicine.medical_specialtyDatabases Factualbusiness.industryPsychological interventionIntensive care unitlanguage.human_languagelaw.inventionGermanClinical pharmacySafety-Based Drug WithdrawalslawAnesthesiologyGermanyAntithromboticEmergency medicinemedicinelanguageAdverse Drug Reaction Reporting SystemsHumansMedication ErrorsPharmacology (medical)Day to daybusinessPharmacy Service HospitalPharmacotherapy
researchProduct

Comparative efficacy of aloe vera mouthwash and chlorhexidine on periodontal health: A randomized controlled trial

2016

Background: With introduction of many herbal medicines, dentistry has recently evidenced shift of approach for treating many inflammatory oral diseases by using such modalities. Aloe vera is one such product exhibiting multiple benefits and has gained considerable importance in clinical research recently. Aims: To compare the efficacy of Aloevera and Chlorhexidine mouthwash on Periodontal Health. Material and Methods: Thirty days randomized controlled trial was conducted among 390 dental students. The students were randomized into two intervention groups namely Aloe Vera (AV) chlorhexidine group (CHX) and one control (placebo) group. Plaque index and gingival index was recorded for each par…

DentistryOdontologíaDental plaquePlacebo030226 pharmacology & pharmacyAloe veralaw.invention03 medical and health sciencesGingivitis0302 clinical medicineRandomized controlled triallawPost-hoc analysismedicineGeneral Dentistrybiologybusiness.industryResearchChlorhexidineSignificant difference030206 dentistrymedicine.diseasebiology.organism_classificationCiencias de la saludCommunity and Preventive DentistryUNESCO::CIENCIAS MÃ DICAS:CIENCIAS MÃ DICAS [UNESCO]medicine.symptombusinessmedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Simultaneous quantification of 18 different phytocannabinoids in serum using a highly sensitive liquid chromatography-tandem mass spectrometry (LC-MS…

2021

Abstract The potential therapeutic effects of various phytocannabinoids and the availability of multiple cannabis-based medicines make it desirable to have an analytical method that simultaneously quantifies a wide range of cannabinoids in blood, beyond delta-9-tetrahydrocannabinol and its metabolites. A liquid chromatography tandem mass spectrometry (LC-MS/MS) method for quantification of 18 phytocannabinoids and cannabinoid metabolites in serum was developed and validated. The method enables simultaneous detection of delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabicyclol, tetrahydrocannabivarin and cannabidivarin and their acidic precursors tet…

Detection limitChromatographyCannabigerol010401 analytical chemistryClinical BiochemistryCell BiologyGeneral MedicineTetrahydrocannabivarin030226 pharmacology & pharmacy01 natural sciencesBiochemistryCannabicyclol0104 chemical sciencesAnalytical Chemistry03 medical and health scienceschemistry.chemical_compoundCannabichromene0302 clinical medicinechemistryLiquid chromatography–mass spectrometrymedicineCannabinolSolid phase extractionmedicine.drugJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

Predictability of drug encapsulation and release from propylene carbonate/PLGA microparticles.

2020

Abstract Key parameters for microparticle-based parenteral depot formulation development are entrapment efficiency and sustained drug release, which both depend on the intermolecular affinity of the components. Here, partial solubility parameters were evaluated as descriptors for 21 drug substances and 3 polymers in propylene carbonate (PC). Out of these 21 drug substances, eight BCS class II substances (celecoxib, clotrimazole, erythromycin, ibuprofen, indomethacin, itraconazole, lopinavir and ritonavir) were encapsulated using PLGA (Poly(DL-lactide-co-glycolide)) as polymer matrix and PC as a polar aprotic solvent in order to assign microparticle properties to potential affinity-related i…

Drug CompoundingPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundPropane0302 clinical medicinePolylactic Acid-Polyglycolic Acid CopolymermedicineLactic AcidMicroparticleSolubilityParticle SizeChemistry021001 nanoscience & nanotechnologyIbuprofenMicrospheresSolventHildebrand solubility parameterPLGAChemical engineeringPharmaceutical PreparationsSolubilityPropylene carbonate0210 nano-technologyGlass transitionPolyglycolic Acidmedicine.drugInternational journal of pharmaceutics
researchProduct

A survey on IVIVC/IVIVR development in the pharmaceutical industry – Past experience and current perspectives

2017

The present work aimed to describe the current status of IVIVC/IVIVR development in the pharmaceutical industry, focusing on the use and perception of specific approaches as well as successful and failed case studies. Two questionnaires have been distributed to 13 EFPIA partners of the Oral Biopharmaceutics Tools Initiative and to the Pharmacokinetics Working Party of the European Medicines Agency in order to capture the perspectives and experiences of industry scientists and agency members, respectively. Responses from ten companies and three European Agencies were received between May 21st 2014 and January 19th 2016. The majority of the companies acknowledged the importance of IVIVC/IVIVR…

Drug IndustryOperations researchPharmaceutical Science02 engineering and technologyModels Biological030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineIVIVCSurveys and QuestionnairesDrug DiscoveryAgency (sociology)AnimalsHumansRelevance (law)MedicinePharmacokineticsMarketingPharmaceutical industryRate of returnFlexibility (engineering)business.industry021001 nanoscience & nanotechnologyDrug developmentPositive attitude0210 nano-technologybusinessEuropean Journal of Pharmaceutical Sciences
researchProduct